These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1975317)

  • 1. Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
    Pyrhönen S; Valtonen M
    Lancet; 1990 Jul; 336(8707):127. PubMed ID: 1975317
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer.
    Porta C; Nastasi G; Spaghi A; Moroni M
    Lancet; 1990 Dec; 336(8728):1454-5. PubMed ID: 1978920
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.
    Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T
    Oncology; 1994; 51(5):396-400. PubMed ID: 8052479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
    Abad A; Rosell R; Barnadas A; Carles J; Ribelles N; Solano V
    Ann Oncol; 1991 Feb; 2(2):153. PubMed ID: 2054318
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy for pancreatic carcinoma.
    Kao GD
    Lancet; 1991 Jan; 337(8734):177. PubMed ID: 1670814
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer.
    Scheithauer W; Funovics J; Mueller C; Ludwig H
    J Cancer Res Clin Oncol; 1990; 116(2):132-3. PubMed ID: 2324155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy in cancers of the gallbladder and bile ducts].
    Okada S; Okazaki N
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1269-72. PubMed ID: 2069397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Dalesio O; Duez N; Blijham G; Planting A; Splinter T; Weber W
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1017-8. PubMed ID: 3478197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
    Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T; Yamauchi H; Ogata Y; Shimada H; Miyakawa S; Yamaguchi A; Sakoda K; Yasuda H; Tsukada K; Yoshida K; Ashida H; Ishikawa Y; Kotoura Y; Kinoshita H; Kajiwara T; Watanabe G; Uchimura M; Funabiki T; Ikeda S; Okada S
    Gan To Kagaku Ryoho; 1996 May; 23(6):707-14. PubMed ID: 8645022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate].
    Scheithauer W; Ludwig H; Zielinski C; Funovics J; Knoflach P; Müller C; Grabner G
    Leber Magen Darm; 1988 Jun; 18(3):149-55. PubMed ID: 3043129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
    Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
    J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
    Cantore M; Fiorentini G; Mambrini A; Rabbi C; Zamagni D; Carlone N; Manni A; Caudana R; Torri T
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):59-64. PubMed ID: 16767908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
    Glimelius B; Hoffman K; Sjödén PO; Jacobsson G; Sellström H; Enander LK; Linné T; Svensson C
    Ann Oncol; 1996 Aug; 7(6):593-600. PubMed ID: 8879373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of metastatic gastric cancer--x-ray follow-up].
    Theobaldy S; Hofmann-Preiss K; Walter M
    Radiologe; 1987 May; 27(5):235-6. PubMed ID: 3615855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.